Publications by authors named "P P Escobar"
Cervical cancer, while preventable through screening and treatment of cervical precancer, remains a global challenge with a disproportionately high burden of disease in resource-limited settings, especially in low- and middle-income countries (LMICs). Lack of affordable, easy-to-use screening and diagnostic tests contributes to this disparity. Most commercially available tests are not appropriate for use in LMICs due to resource constraints.
View Article and Find Full Text PDFArticle Synopsis
- In human health risk assessment, genotoxicity hazards of chemicals typically start with a set of in vitro tests, but these tests don't capture all potential genotoxic endpoints, leading to sometimes contradictory results.
- Mathematical modeling can improve the interpretation of these tests by accounting for each test's strengths and weaknesses, providing objective predictions with associated uncertainties.
- A study found that combining a mammalian in vitro clastogenicity test and a gene mutation test offers strong evidence for genotoxic hazard assessment, but the bacterial reverse mutation (Ames) test alone can still provide useful evidence when no other data is available.
Background: The incidence of femur fractures has increased in recent years, along with the rate of surgery and subsequent nonunion following these fractures. Nonunion is a significant concern due to the burden it places on both patients and the healthcare system. This study aims to investigate the demographic factors associated with femoral shaft fracture nonunion by comparing two surgical management approaches: open reduction internal fixation (ORIF) with plating versus closed reduction and fixation using intramedullary nailing (IMN).
View Article and Find Full Text PDFBackground: This study aimed to determine if the neoadjuvant (NAT) KEYNOTE-522 regimen was associated with higher rates of pathologic complete response (pCR), corresponding to higher rates of breast conservation therapy (BCT) in early-stage triple-negative breast cancer (TNBC) patients.
Patients And Methods: Stage II-III TNBC patients diagnosed between 2019 and 2022 who underwent NAT were analyzed retrospectively. NAT with KEYNOTE-522 versus control NAT were compared for rates of BCT, axillary node dissection (ALND), pCR, and survival outcomes.